Data-quality flags on India
HIV tests performed with the result returned to the person, 2020 (PEPFAR Panorama Spotlight). The value moved from 134,906 in 2019 to 12,003 in 2020, a change of more than threefold in a single year. The move from 134,906 to 12,003 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2019 and 2020 are not comparable. Check the figures by reporting organisation before reading a trend across 2019 and 2020.
HIV tests performed with the result returned to the person, 2021 (PEPFAR Panorama Spotlight). The value moved from 12,003 in 2020 to 43,056 in 2021, a change of more than threefold in a single year. The move from 12,003 to 43,056 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2020 and 2021 are not comparable. Check the figures by reporting organisation before reading a trend across 2020 and 2021.
People receiving PrEP, 2022 (PEPFAR Panorama Spotlight). The value moved from 15 in 2021 to 279 in 2022, a change of more than threefold in a single year. The move from 15 to 279 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2021 and 2022 are not comparable. Check the figures by reporting organisation before reading a trend across 2021 and 2022.
People receiving PrEP, 2023 (PEPFAR Panorama Spotlight). The value moved from 279 in 2022 to 1,603 in 2023, a change of more than threefold in a single year. The move from 279 to 1,603 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2022 and 2023 are not comparable. Check the figures by reporting organisation before reading a trend across 2022 and 2023.
Number of PLHIV virally suppressed (VL<1000), 2019 (PEPFAR Panorama Spotlight). The value moved from 14,237 in 2018 to 69,222 in 2019, a change of more than threefold in a single year. The move from 14,237 to 69,222 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2018 and 2019 are not comparable. Check the figures by reporting organisation before reading a trend across 2018 and 2019.
Sources of the figures for India
| Source | Type | Rows | Indicators | Years | Read from | Retrieved |
|---|---|---|---|---|---|---|
| PEPFAR results by province | Programme record | 318 | 7 | 2016–2025 | data.pepfar.gov | 2026-10-12 |
| Demographic and Health Surveys | Survey | 313 | 4 | 2006–2020 | api.dhsprogram.com | 2026-10-16 |
| WHO Global Tuberculosis Programme | Programme record | 177 | 17 | 2000–2025 | extranet.who.int | 2026-10-16 |
| UNAIDS AIDSinfo | Modelled estimate | 172 | 26 | 2000–2024 | aidsinfo.unaids.org | 2026-10-20 |
| PEPFAR results by funding agency and province | Programme record | 147 | 9 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| National AIDS Control Organisation of India, Sankalak 2025, seventh edition | Modelled estimate | 140 | 4 | 2024 | naco.mohfw.gov.in | 2026-10-21 |
| ForeignAssistance.gov | Expenditure account | 92 | 5 | 2002–2026 | foreignassistance.gov | 2026-10-29 |
| OECD Creditor Reporting System | Expenditure account | 66 | 3 | 2002–2024 | sdmx.oecd.org | 2026-10-12 |
| IATI, through d-portal | Expenditure account | 65 | 3 | 2000–2026 | d-portal.org | 2026-10-12 |
| PEPFAR results by funding agency | Programme record | 53 | 9 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| PEPFAR Panorama Spotlight | Programme record | 52 | 7 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| PEPFAR testing by modality | Programme record | 48 | 6 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| UNAIDS Global AIDS Monitoring expenditure database | Expenditure account | 47 | 6 | 2017–2024 | hivfinancial.unaids.org | 2026-10-12 |
| PEPFAR budgets and expenditure | Expenditure account | 40 | 8 | 2021–2025 | data.pepfar.gov | 2026-10-12 |
| Global Fund Data Service | Programme record | 39 | 8 | 2017–2025 | fetch.theglobalfund.org | 2026-10-12 |
| CLM Asia | Community-led monitoring | 30 | 8 | 2023–2026 | data.clm-asia.org | 2026-10-14 |
| UNICEF HIV/AIDS dataset | Modelled estimate | 28 | 4 | 2025 | sdmx.data.unicef.org | 2026-10-20 |
| World Bank Open Data | Modelled estimate | 27 | 2 | 2000–2025 | api.worldbank.org | 2026-10-12 |
| WHO HIV testing services dashboard | Programme record | 26 | 3 | 2018–2024 | eic-database-290813.ew.r.appspot.com | 2026-10-14 |
| PEPFAR operating-unit budgets | Expenditure account | 18 | 2 | 2006–2020 | data.pepfar.gov | 2026-10-12 |
| WHO Global Health Observatory | Modelled estimate | 16 | 12 | 2022–2025 | ghoapi.azureedge.net | 2026-10-12 |
| UNAIDS Data 2025 country databook | Expenditure account | 6 | 1 | 2017–2023 | aidsinfo.unaids.org | 2026-10-15 |
| Global Fund allocations | Expenditure account | 4 | 1 | 2017–2026 | fetch.theglobalfund.org | 2026-10-12 |
| PEPFAR commodity procurement plans | Expenditure account | 4 | 4 | 2021 | data.pepfar.gov | 2026-10-12 |
| PEPFAR human resources for health inventory | Expenditure account | 3 | 3 | 2025 | data.pepfar.gov | 2026-10-12 |
Indicators held
| Indicator | Domain | Unit | Rows | Years | Sources | Most recent value |
|---|---|---|---|---|---|---|
| Actual expenditure on collaborative TB/HIV activities | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $1.3m (2024) |
| Budget required for collaborative TB/HIV activities | Financing | USD | 8 | 2018–2025 | WHO Global Tuberculosis Programme | $1.4m (2025) |
| Country-reported HIV expenditure, all sources | Financing | USD | 18 | 2012–2024 | UNAIDS AIDSinfo, UNAIDS Global AIDS Monitoring expenditure database | $334.1m (2024) |
| Domestic funding received by the national TB programme | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $436.5m (2024) |
| Domestic public HIV expenditure | Financing | USD | 14 | 2017–2024 | UNAIDS Data 2025 country databook, UNAIDS Global AIDS Monitoring expenditure database | $334.1m (2024) |
| Expected Global Fund funding for the national TB programme | Financing | USD | 8 | 2018–2025 | WHO Global Tuberculosis Programme | $15.4m (2025) |
| Expected USAID funding for the national TB programme | Financing | USD | 7 | 2018–2024 | WHO Global Tuberculosis Programme | $20.0m (2024) |
| Expected domestic funding for the national TB programme | Financing | USD | 8 | 2018–2025 | WHO Global Tuberculosis Programme | $688.8m (2025) |
| Expected funding for collaborative TB/HIV activities | Financing | USD | 8 | 2018–2025 | WHO Global Tuberculosis Programme | $1.4m (2025) |
| External HIV financing (all donors, ODA) | Financing | USD | 23 | 2002–2024 | OECD Creditor Reporting System | $68.0m (2024) |
| External HIV financing from governments other than the United States (IATI) | Financing | USD | 27 | 2000–2026 | IATI, through d-portal | $617k (2026) |
| External HIV financing from multilateral bodies other than the Global Fund (IATI) | Financing | USD | 15 | 2012–2026 | IATI, through d-portal | $2.6m (2026) |
| External HIV financing from the United States (ODA) | Financing | USD | 48 | 2002–2026 | ForeignAssistance.gov, OECD Creditor Reporting System | $4.6m (2026) |
| Funding received for collaborative TB/HIV activities | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $1.3m (2024) |
| Global Fund HIV allocation for a whole three-year cycle, not an annual figure | Financing | USD per three-year allocation cycle | 4 | 2017–2026 | Global Fund allocations | 100,000,000 (2026) |
| Global Fund HIV disbursements to the country | Financing | USD | 43 | 2004–2026 | IATI, through d-portal, OECD Creditor Reporting System | $26.2m (2026) |
| Global Fund funding received by the national TB programme | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $18.7m (2024) |
| HIV spending on governance and sustainability | Financing | USD | 8 | 2017–2024 | UNAIDS Global AIDS Monitoring expenditure database | $28.4m (2024) |
| HIV spending on prevention | Financing | USD | 8 | 2017–2024 | UNAIDS Global AIDS Monitoring expenditure database | $80.6m (2024) |
| HIV spending on programmes for children and adolescents | Financing | USD | 7 | 2017–2023 | UNAIDS Global AIDS Monitoring expenditure database | $9.1m (2023) |
| HIV spending on treatment, care and support | Financing | USD | 8 | 2017–2024 | UNAIDS Global AIDS Monitoring expenditure database | $192.9m (2024) |
| PEPFAR expenditure, HHS/CDC | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $6.3m (2025) |
| PEPFAR expenditure, USAID | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $1.3m (2025) |
| PEPFAR expenditure, all US agencies | Financing | USD | 8 | 2018–2025 | PEPFAR budgets and expenditure, PEPFAR operating-unit budgets | $8.9m (2025) |
| PEPFAR expenditure, other US agencies | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $1.3m (2025) |
| PEPFAR planned commodity procurement, like for like | Financing | USD | 1 | 2021 | PEPFAR commodity procurement plans | $335k (2021) |
| PEPFAR planned funding (budget), all US agencies | Financing | USD | 20 | 2006–2025 | PEPFAR budgets and expenditure, PEPFAR operating-unit budgets | $24.5m (2025) |
| PEPFAR planned funding, HHS/CDC | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $11.8m (2025) |
| PEPFAR planned funding, USAID | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $11.2m (2025) |
| PEPFAR planned funding, other US agencies | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $1.5m (2025) |
| PEPFAR planned procurement of antiretroviral drugs | Financing | USD | 1 | 2021 | PEPFAR commodity procurement plans | $0 (2021) |
| PEPFAR planned procurement of laboratory commodities | Financing | USD | 1 | 2021 | PEPFAR commodity procurement plans | $60k (2021) |
| PEPFAR planned procurement of rapid test kits | Financing | USD | 1 | 2021 | PEPFAR commodity procurement plans | $0 (2021) |
| PEPFAR spend on staff, human resources for health inventory | Financing | USD | 1 | 2025 | PEPFAR human resources for health inventory | $5.2m (2025) |
| PEPFAR-funded staff delivering services, full-time equivalents | Financing | count | 1 | 2025 | PEPFAR human resources for health inventory | 308 (2025) |
| PEPFAR-funded staff, full-time equivalents | Financing | count | 1 | 2025 | PEPFAR human resources for health inventory | 510 (2025) |
| US HIV disbursements managed by Health and Human Services | Financing | USD | 24 | 2003–2026 | ForeignAssistance.gov | $2.6m (2026) |
| US HIV disbursements managed by USAID | Financing | USD | 25 | 2002–2026 | ForeignAssistance.gov | $-376k (2026) |
| US HIV disbursements managed by other US agencies | Financing | USD | 16 | 2005–2021 | ForeignAssistance.gov | $0 (2021) |
| US HIV disbursements managed by the State Department | Financing | USD | 2 | 2025–2026 | ForeignAssistance.gov | $2.4m (2026) |
| USAID funding received by the national TB programme | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $20.0m (2024) |
| % of ALL PLHIV who are virally suppressed | Treatment cascade | percent | 4 | 2022–2025 | UNAIDS AIDSinfo, WHO Global Health Observatory | 74.0% (2025) |
| % of PLHIV on ART (second 95, PLHIV base) | Treatment cascade | percent | 9 | 2022–2025 | UNAIDS AIDSinfo, WHO Global Health Observatory | 77.0% (2025) |
| % of PLHIV who have been diagnosed (first 95) | Treatment cascade | percent | 8 | 2022–2025 | UNAIDS AIDSinfo, WHO Global Health Observatory | 88.0% (2025) |
| % of estimated HIV-positive incident TB cases on TB treatment and ART | Treatment cascade | percent | 18 | 2007–2024 | UNAIDS AIDSinfo | 87.0% (2024) |
| % of people currently enrolled in HIV treatment started on TB preventive therapy | Treatment cascade | percent | 3 | 2018–2020 | UNAIDS AIDSinfo | 25.1% (2020) |
| % of people living with HIV on ART who completed a course of TB preventive therapy | Treatment cascade | percent | 1 | 2019 | UNAIDS AIDSinfo | 85.7% (2019) |
| % of people newly enrolled in HIV treatment diagnosed with TB disease | Treatment cascade | percent | 8 | 2013–2020 | UNAIDS AIDSinfo | 16.0% (2020) |
| % of people newly enrolled in HIV treatment started on TB preventive therapy | Treatment cascade | percent | 5 | 2016–2020 | UNAIDS AIDSinfo | 39.0% (2020) |
| % of people on ART who are virally suppressed (third 95) | Treatment cascade | percent | 45 | 2018–2025 | PEPFAR results by province, WHO Global Health Observatory | 96.0% (2025) |
| % of returned HIV test results that were positive | Treatment cascade | percent | 17 | 2018–2024 | UNAIDS AIDSinfo, WHO Global Health Observatory, WHO HIV testing services dashboard | 0.3% (2024) |
| HIV tests performed at a health facility | Treatment cascade | count | 14 | 2018–2025 | PEPFAR testing by modality, WHO HIV testing services dashboard | 26,110 (2025) |
| HIV tests performed through community outreach | Treatment cascade | count | 8 | 2018–2025 | PEPFAR testing by modality | 6,131 (2025) |
| HIV tests performed with the result returned to the person | Treatment cascade | count | 91 | 2016–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, PEPFAR results by province, PEPFAR testing by modality, UNAIDS AIDSinfo, WHO Global Health Observatory, WHO HIV testing services dashboard | 32,241 (2025) |
| HIV-exposed infants tested within two months of birth | Treatment cascade | percent | 1 | 2024 | UNAIDS AIDSinfo | 67.0% (2024) |
| HIV-positive TB patients started or continued on ART | Treatment cascade | count | 16 | 2015–2024 | Global Fund Data Service, WHO Global Tuberculosis Programme | 32,361 (2024) |
| New HIV diagnoses with a CD4 count below 200 | Treatment cascade | percent | 5 | 2016–2020 | UNAIDS AIDSinfo | 41.0% (2020) |
| Newly diagnosed at HHS/CDC-funded partners (MER HTS_TST_POS) | Treatment cascade | count | 37 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 2,891 (2025) |
| Newly diagnosed at USAID-funded partners (MER HTS_TST_POS) | Treatment cascade | count | 22 | 2018–2024 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 4,649 (2024) |
| Newly diagnosed at other US-agency partners (MER HTS_TST_POS) | Treatment cascade | count | 9 | 2020–2021 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 1,574 (2021) |
| Newly enrolled on ART at HHS/CDC-funded partners (MER TX_NEW) | Treatment cascade | count | 27 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 3,971 (2025) |
| Newly enrolled on ART at USAID-funded partners (MER TX_NEW) | Treatment cascade | count | 14 | 2020–2024 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 10,452 (2024) |
| Newly enrolled on ART at other US-agency partners (MER TX_NEW) | Treatment cascade | count | 25 | 2018–2022 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 7,668 (2022) |
| Number newly diagnosed HIV-positive (PEPFAR MER HTS_TST_POS) | Treatment cascade | count | 70 | 2016–2025 | PEPFAR Panorama Spotlight, PEPFAR results by province, PEPFAR testing by modality | 2,891 (2025) |
| Number of PLHIV virally suppressed (VL<1000) | Treatment cascade | count | 52 | 2018–2025 | PEPFAR Panorama Spotlight, PEPFAR results by province | 234,560 (2025) |
| Number of people on ART (PEPFAR MER TX_CURR) | Treatment cascade | count | 76 | 2016–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, PEPFAR results by province, UNAIDS AIDSinfo, WHO Global Health Observatory, WHO Global Tuberculosis Programme | 1,975,200 (2025) |
| PMTCT ART coverage among pregnant women with HIV | Treatment cascade | percent | 9 | 2016–2025 | UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset | 89.0% (2025) |
| People living with HIV in care screened for TB | Treatment cascade | count | 5 | 2017–2021 | Global Fund Data Service | 407,578 (2021) |
| People living with HIV on ART who started TB preventive therapy | Treatment cascade | count | 5 | 2017–2021 | Global Fund Data Service | 157,628 (2021) |
| People newly diagnosed at a health facility | Treatment cascade | count | 8 | 2018–2025 | PEPFAR testing by modality | 2,479 (2025) |
| People newly diagnosed through community outreach | Treatment cascade | count | 8 | 2018–2025 | PEPFAR testing by modality | 412 (2025) |
| People newly enrolled on ART during the year | Treatment cascade | count | 69 | 2013–2025 | PEPFAR Panorama Spotlight, PEPFAR results by province, WHO Global Tuberculosis Programme | 3,971 (2025) |
| People on ART at HHS/CDC-funded partners (MER TX_CURR) | Treatment cascade | count | 27 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 276,015 (2025) |
| People on ART at USAID-funded partners (MER TX_CURR) | Treatment cascade | count | 14 | 2020–2024 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 128,412 (2024) |
| People on ART at other US-agency partners (MER TX_CURR) | Treatment cascade | count | 25 | 2018–2022 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 73,776 (2022) |
| People tested for HIV in the last 12 months who received the result (household survey) | Treatment cascade | percent | 136 | 2006–2020 | Demographic and Health Surveys | By population group, sex or age only, to 2020 |
| People who completed a course of TB preventive therapy | Treatment cascade | count | 7 | 2018–2025 | PEPFAR Panorama Spotlight | 10,186 (2025) |
| Pregnant women with HIV who received ARVs for PMTCT | Treatment cascade | count | 5 | 2017–2025 | Global Fund Data Service, WHO Global Health Observatory | 17,793 (2025) |
| TB patients recorded as HIV-positive | Treatment cascade | count | 12 | 2015–2024 | WHO Global Tuberculosis Programme | 33,190 (2024) |
| TB patients with an HIV test result recorded | Treatment cascade | count | 20 | 2015–2024 | Global Fund Data Service, WHO Global Tuberculosis Programme | 2,416,094 (2024) |
| AIDS-related deaths | Epidemic estimates | count | 48 | 2024–2025 | National AIDS Control Organisation of India, Sankalak 2025, seventh edition, UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory | 25,000 (2025) |
| Deaths from TB among people living with HIV | Epidemic estimates | count | 50 | 2000–2024 | UNAIDS AIDSinfo, WHO Global Tuberculosis Programme | 5,300 (2024) |
| HIV prevalence among a key population | Epidemic estimates | percent | 5 | 2024 | UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| HIV prevalence, ages 15-49 | Epidemic estimates | percent | 49 | 2006–2024 | Demographic and Health Surveys, National AIDS Control Organisation of India, Sankalak 2025, seventh edition, UNAIDS AIDSinfo, World Bank Open Data | 0.2% (2024) |
| Incident TB cases among people living with HIV | Epidemic estimates | count | 50 | 2000–2024 | UNAIDS AIDSinfo, WHO Global Tuberculosis Programme | 37,000 (2024) |
| New HIV infections | Epidemic estimates | count | 48 | 2024–2025 | National AIDS Control Organisation of India, Sankalak 2025, seventh edition, UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory | 60,000 (2025) |
| People living with HIV | Epidemic estimates | count | 48 | 2024–2025 | National AIDS Control Organisation of India, Sankalak 2025, seventh edition, UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory | 2,600,000 (2025) |
| Condom use at last higher-risk sex (household survey) | Prevention and outreach | percent | 23 | 2006–2020 | Demographic and Health Surveys | By population group, sex or age only, to 2020 |
| Key-population people reached by outreach (count over the period) | Prevention and outreach | count | 3 | 2021–2023 | Global Fund Data Service | By population group, sex or age only, to 2023 |
| Male condoms distributed in a year | Prevention and outreach | count | 5 | 2019–2024 | UNAIDS AIDSinfo | 325,716,075 (2024) |
| People receiving PrEP | Prevention and outreach | count | 21 | 2020–2024 | PEPFAR Panorama Spotlight, PEPFAR results by province, UNAIDS AIDSinfo | 1,277 (2024) |
| People with comprehensive correct knowledge of HIV (household survey) | Prevention and outreach | percent | 142 | 2006–2020 | Demographic and Health Surveys | By population group, sex or age only, to 2020 |
| Enough staff to meet the needs of service users (CLM) | Service access | percent | 4 | 2023–2026 | CLM Asia | 42.0% (2026) |
| Ever stopped antiretroviral treatment (CLM) | Service access | percent | 2 | 2023–2024 | CLM Asia | 8.1% (2024) |
| Faced stigma or discrimination at the facility in the last six months (CLM) | Service access | percent | 4 | 2023–2026 | CLM Asia | 0.0% (2026) |
| Facility opens and closes on time (CLM) | Service access | percent | 4 | 2023–2026 | CLM Asia | 40.8% (2026) |
| Left facility without ARV or OI medicines because of a stockout in the last three months (CLM) | Service access | percent | 4 | 2023–2026 | CLM Asia | 0.0% (2026) |
| Paid out of pocket for medicines or tests in the last six months (CLM) | Service access | percent | 4 | 2023–2026 | CLM Asia | 71.0% (2026) |
| Psychosocial support available for PLHIV (CLM) | Service access | percent | 4 | 2023–2026 | CLM Asia | 90.0% (2026) |
| Service user knows own viral load (CLM) | Service access | percent | 4 | 2023–2026 | CLM Asia | 91.9% (2026) |
| Estimated pregnant women with HIV needing ARVs for PMTCT | Population denominators | count | 9 | 2016–2025 | UNAIDS AIDSinfo, WHO Global Health Observatory | 20,000 (2025) |
| Estimated size of a key population | Population denominators | count | 5 | 2024 | UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| Total population | Population denominators | count | 26 | 2000–2025 | World Bank Open Data | 1,463,865,525 (2025) |
Every row shown on the India page is in the panel download, with the source URL and the retrieval date of the row attached. See Data.
Turn your phone to read the chart upright